• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » HeartWare lands FDA OK to enroll another cohort in ongoing VAD study

HeartWare lands FDA OK to enroll another cohort in ongoing VAD study

August 29, 2013 By Ingrid Mezo

HeartWare lands FDA OK to enroll another arm in ongoing VAD study

HeartWare International (NSDQ:HTWR) won an Investigational Device Exemption (IDE) supplement from the FDA to add another patient group to its ongoing ENDURANCE trial, this time examining the impact of blood pressure monitoring on neurological outcomes.

Researchers are evaluating the use of the HeartWare’s ventricular assist device (VAD) as a final or destination therapy for heart failure patients who are too sick for a heart transplant and have not responded to other therapies. The device is already approved in the U.S. as a bridge to cardiac transplantation, the Framingham, Mass.-based company noted.

This news comes on the heels of a shakeup of HeartWare’s stock after a financial analyst cited "glaring inconsistencies" between statements made by a principal investigator for the ENDURANCE trial for VAD as destination therapy and remarks made by the company’s CEO on calls with financial analysts.

The FDA in June granted HeartWare conditional approval for an expansion of ENDURANCE to evaluate the effect of closer blood pressure monitoring on neurological events. The newest patient group is intended to help confirm clinical observations that more regular monitoring and management of patient blood pressure results in fewer neurological events, according to a press release.  

HeartWare won permission to enroll up to 286 VAD patients as well as up to 143 control patients in the new supplemental group, and the company plans to follow them for 12 months following implant. Data from both this new group and ENDURANCE will be incorporated into HeartWare’s anticipated pre-market approval application for the device.

In addition to U.S. approval as a bridge to transplant therapy, the HeartWare VAD has a CE Mark in Europe, and has been used to treat patients in 35 countries, the firm said. HeartWare added that it expects to complete enrollment for the post-approval study of 600 patients for HVAD as a bridge to cardiac transplantation by the end of this year.

HTWR shares ticked up 0.6% today to $80.79 apiece as of about 12:45 p.m.

Filed Under: Food & Drug Administration (FDA), News Well, Regulatory/Compliance, Structural Heart Tagged With: Cardiac Rhythm Management, Clinical Trials, HeartWare International Inc.

More recent news

  • EBR Systems raises $36.1M for leadless pacing tech
  • The biggest cardiovascular tech news out of EuroPCR 2025
  • CardiaWave has positive 12-month Valvosoft results
  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Medtronic has new Cardiovascular, CST leaders after longtime exec departs

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy